Can Moderna sustain its comeback beyond COVID vaccines and intismeran?
Moderna returned to quarterly profit and raised 2026 growth guidance, but international COVID sales still drive much of the rebound.
Pharma & Biotech
Pharma & Biotech
Is mRNA-1010 the breakthrough Moderna needs beyond COVID-19 vaccines?
Moderna’s mRNA-1010 has cleared a major regulatory hurdle, but evidence in older adults, higher reactogenicity and seasonal contracting could limit its early impact.